CXCR4 over-expression and survival in cancer: A system review and meta-analysis
作者： Hongli Zhao , Liyuan Guo , Hong Zhao , Jiaxin Zhao , Hao Weng
关键词:
摘要: C-X-C chemokine receptor 4 (CXCR4) is frequently over-expressed in various types of cancer; many agents against CXCR4 are clinical development currently despite variable data for the prognostic impact expression. Here eighty-five studies with a total 11,032 subjects were included to explore association between and progression-free survival (PFS) or overall (OS) cancer. Pooled analysis shows that over-expression significantly associated poorer PFS (HR 2.04; 95% CI, 1.72-2.42) OS (HR=1.94; 1.71-2.20) irrespective cancer types. Subgroup indicates significant shorter hematological malignancy, breast cancer, colorectal esophageal renal gynecologic pancreatic liver effects remained consistent across age, risk bias, levels adjustment, median follow-up period, geographical area, detection methods, publication year size studies. predicts unfavorable head neck lung prostate gallbladder these independence year, methods period. In conclusion, poor prognosis
impactjournals.com参考文章(106)
Guorong Li, Jacques Tostain, Anne Gentil-Perret, Michel Péoc'h, Marc Gigante, An Zhao, Grégory Badin, Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma. Histology and Histopathology. ,vol. 28, pp. 1217- 1222 ,(2013) , 10.14670/HH-28.1217
Marcello Ferretti Fanelli, Ludmilla T Domingos Chinen, Maria Dirlei Begnami, Wilson Luis Costa, José Humberto T Fregnami, Fernando A Soares, André Luis Montagnini, The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. ,vol. 61, pp. 153- 161 ,(2012) , 10.1111/J.1365-2559.2011.04139.X
A. Caruz, M. Samsom, J.M. Alonso, J. Alcami, F. Baleux, J.L. Virelizier, M. Parmentier, F. Arenzana-Seisdedos, Genomic organization and promoter characterization of human CXCR4 gene1 FEBS Letters. ,vol. 426, pp. 271- 278 ,(1998) , 10.1016/S0014-5793(98)00359-7
C.-L. Lu, J. Guo, J. Gu, D. Ge, Y.-Y. Hou, Z.-W. Lin, J.-Y. Ding, CXCR4 heterogeneous expression in esophageal squamous cell cancer and stronger metastatic potential with CXCR4-positive cancer cells Diseases of The Esophagus. ,vol. 27, pp. 294- 302 ,(2014) , 10.1111/DOTE.12100
Guifeng Liu, Xuewei Zhu, Xiaozhen Wang, Shaonan Yu, Yan Chen, High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome. Acta Medica Okayama. ,vol. 67, pp. 369- 375 ,(2013) , 10.18926/AMO/52010
Yaling Liu, Yu Zhou, Xiao Feng, Pengchun Yang, Jingfang Yang, Ping An, Hao Wang, Shicai Ye, Caiyuan Yu, Yanting He, Hesheng Luo, Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes, Chromosomes and Cancer. ,vol. 53, pp. 358- 365 ,(2014) , 10.1002/GCC.22146
C. L. Lu, Y. Ji, D. Ge, J. Guo, J. Y. Ding, The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer. Diseases of The Esophagus. ,vol. 24, pp. 283- 290 ,(2011) , 10.1111/J.1442-2050.2010.01135.X
Colin B. Begg, Madhuchhanda Mazumdar, Operating characteristics of a rank correlation test for publication bias. Biometrics. ,vol. 50, pp. 1088- 1101 ,(1994) , 10.2307/2533446
Yoshinao Oda, Yoshihiro Ohishi, Yuji Basaki, Hiroaki Kobayashi, Toshio Hirakawa, Norio Wake, Mayumi Ono, Kazuto Nishio, Michihiko Kuwano, Masazumi Tsuneyoshi, Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/MVP and P-glycoprotein expression Cancer Science. ,vol. 98, pp. 1020- 1026 ,(2007) , 10.1111/J.1349-7006.2007.00492.X
Zhigang Zhang, Chao Ni, Wuzhen Chen, Ping Wu, Zhen Wang, Junhua Yin, Jian Huang, Fuming Qiu, None, Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer. ,vol. 14, pp. 49- 49 ,(2014) , 10.1186/1471-2407-14-49